Identification of prognosis-relevant subgroups in patients with chemoresistant triple-negative breast cancer

Ke Da Yu, Rui Zhu, Ming Zhan, Angel A. Rodriguez, Wei Yang, Stephen Wong, Andreas Makris, Brian D. Lehmann, Xi Chen, Ingrid Mayer, Jennifer A. Pietenpol, Zhi Ming Shao, W. Fraser Symmans, Jenny C. Chang

Research output: Contribution to journalArticle

89 Scopus citations

Abstract

Purpose: Patients with triple-negative breast cancer (TNBC) and residual disease after neoadjuvant chemotherapy generally have worse outcome; however, some patients with residual tumor after neoadjuvant chemotherapy do not relapse. Wehypothesize that there are subgroups of patients with chemoresistant TNBC with different prognosis. Experimental Design: Forty-nine chemoresistant cases from 111 patients with TNBC treated with neoadjuvant chemotherapy (M.D. Anderson Cancer Center, Houston, TX) constituted the discovery cohort, and 25 chemoresistant samples from 47 neoadjuvant chemotherapy-treated TNBC (The Methodist Hospital, Houston, TX) were chosen for validation. Extended validation was carried out in 269 operable TNBC predicted to be chemoresistant by expression pattern from published datasets. Results: Weestablished a seven-gene prognostic signature using dChip and gene set enrichment analyses. In the independent validation cohort, the classifier predicted correctly with positive predictive value of 75.0% and negative predictive value (i.e., relapse-free survival; RFS) of 76.9% at 3 years. Those predicted to relapse had a HR of 4.67 [95% confidence interval (CI): 1.27-17.15] for relapse in 3 years. In extended validation, patients predicted not to relapse exhibited 3-year RFS of 78.9%, whereas the 3-year RFS was 48.5% for patients predicted to relapse, with HR of 2.61 (95% CI: 1.52-4.49). The TNBC subgroup that predicted to have relatively favorable prognosis was characterized by high expression of "luminal- like" genes [androgen-receptor (AR) and GATA3], whereas the subgroup with worse prognosis was characterized by expression of cancer stem-cell markers. Conclusion: We developed a clinically relevant signature for patients with chemoresistant TNBC. For these women, new therapeutic strategies like targeting AR activation or cancer stem cells may need to be developed.

Original languageEnglish (US)
Pages (from-to)2723-2733
Number of pages11
JournalClinical Cancer Research
Volume19
Issue number10
DOIs
StatePublished - May 15 2013

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Fingerprint Dive into the research topics of 'Identification of prognosis-relevant subgroups in patients with chemoresistant triple-negative breast cancer'. Together they form a unique fingerprint.

  • Cite this

    Yu, K. D., Zhu, R., Zhan, M., Rodriguez, A. A., Yang, W., Wong, S., Makris, A., Lehmann, B. D., Chen, X., Mayer, I., Pietenpol, J. A., Shao, Z. M., Symmans, W. F., & Chang, J. C. (2013). Identification of prognosis-relevant subgroups in patients with chemoresistant triple-negative breast cancer. Clinical Cancer Research, 19(10), 2723-2733. https://doi.org/10.1158/1078-0432.CCR-12-2986